Analyst Reports
English reports
Analysguiden
2022-18-11 | Analysguiden - Promising long-term data
13 Jun 2022 | Analyseguiden - Preparing for the final
8 Mar 2022 | Analysguiden - A moving target
9 Dec 2021 | Analysguiden - Solid data open for final phase
19 Nov 2021 | Analysguiden - Phase 2 data pending
23 Aug 2021 | Analysguiden - Funding still pending
22 Apr 2021 | Analysguiden - First human data reassuring
27 Jan 2021 | Analysguiden - Getting Close To Patients
3 Sep 2020 | Analysguiden - Broadening the Portfolio
21 Nov 2019 | Analysguiden - Potential at Reduced Risk
Pareto Securities
17 November 2022 Pareto | 9M 2022 Report Newsflash
24 Oct 2022 Pareto | ES2B-C001 positive preclinical data published
18 Oct 2022 Pareto | ABNCoV2 reports positive phase II durability data
22 Sep 2022 Pareto | COVID vaccine phase III trial ongoing
8 Apr 2022 Pareto | Cash position to be further increased
1 Mar 2022 Pareto | Further progress with COVID-19 vaccine
10 Jan 2022 Pareto | Exciting topline preclinical results for ES2B-C001
7 Dec 2021 | Pareto - Great ABNCoV2 Phase II top line results
17 Nov 2021 | Pareto - COVID-19 vaccine Phase II readout on the horizon
20 Aug 2021 | Pareto - Initiation of Phase II trial just around the corner
9 Aug 2021 | Pareto - Great COUGH-1 headline results
24 Jun 2021 | Pareto - Rights to COVID-19 Challenge (Initiation)
Swedish reports
Analysguiden
2022-18-11 | Analysguiden - Lovande långtidsdata
13 Jun 2022 | Analysguiden - Bavarian nära fas 3-start
8 Mar 2022 | Analysguiden - Ett rörligt mål
9 Dec 2021 | Analysguiden - Resultat öppnar vägen för slutfas
19 Nov 2021 | Analysguiden - Fas 2-resultat inom kort
23 Aug 2021 | Analysguiden - I väntan på finansiering
22 Apr 2021 | Analysguiden - Första data på människa
27 Jan 2021 | Analysguiden -Test På Människa Inom Kort
3 Sep 2020 | Analysguiden - Minskad risk med breddad portfölj